Figure 5 | Scientific Reports

Figure 5

From: Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells

Figure 5

Inhibition of AKR1C activities reverses cisplatin resistance in UM-UC-3-liver- and bone metastatic cells.

(a) AKR1C1, AKR1C2, and AKR1C3 mRNA expression levels in UM-UC-3 cells treated with or without 1 μM cisplatin for 1 month were examined by real-time RT-PCR. (b) AKR1C2 and AKR1C3 mRNA expression levels among UM-UC-3 sublines were examined by real-time RT-PCR. (c,d) Sensitivity of UM-UC-3 sublines to cisplatin. UM-UC-3 sublines were treated with cisplatin at the indicated concentrations for 3 days, and cell viability was calculated as a percentage with respect to the control (DMSO). (d) The IC50 value is displayed on the graph. *P < 0.05 vs. WT. (e) Effects of AKR1C inhibitor FFA on cisplatin resistance in UM-CU-3 metastatic cells. UM-UC-3-control, primary bladder, and liver and bone metastatic cells were treated with 5 μM cisplatin for 72 h combined with either 10 μM FFA or DMSO. *P < 0.05 vs. DMSO.

Back to article page